Vericel (NASDAQ:VCEL) Insider Sean Flynn Sells 15,000 Shares of Stock

Vericel Corporation (NASDAQ:VCEL) insider Sean Flynn sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $40.21, for a total value of $603,150.00. Following the transaction, the insider directly owned 1,647 shares in the company, valued at $66,225.87. This trade represents a 90.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Vericel Trading Up 0.9%

Shares of Vericel stock traded up $0.37 on Monday, reaching $40.47. 595,944 shares of the company were exchanged, compared to its average volume of 605,152. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of 96.36 and a beta of 1.12. Vericel Corporation has a one year low of $28.95 and a one year high of $43.57. The company has a 50-day moving average of $35.32 and a 200 day moving average of $35.62.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03. The business had revenue of $68.43 million during the quarter, compared to analysts’ expectations of $63.68 million. Vericel had a net margin of 7.35% and a return on equity of 6.41%. The firm’s revenue was up 30.1% on a year-over-year basis. During the same period last year, the business earned ($0.23) earnings per share. Analysts predict that Vericel Corporation will post 0.49 earnings per share for the current year.

Hedge Funds Weigh In On Vericel

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Huntington National Bank increased its holdings in shares of Vericel by 51.3% in the third quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 273 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in shares of Vericel by 1.4% during the 4th quarter. State of Alaska Department of Revenue now owns 25,744 shares of the biotechnology company’s stock worth $927,000 after buying an additional 353 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Vericel by 13.7% during the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after buying an additional 353 shares during the period. California State Teachers Retirement System boosted its holdings in shares of Vericel by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 45,404 shares of the biotechnology company’s stock worth $1,932,000 after buying an additional 382 shares during the period. Finally, Commonwealth Equity Services LLC grew its stake in Vericel by 3.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 11,698 shares of the biotechnology company’s stock valued at $421,000 after buying an additional 410 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on VCEL. Weiss Ratings raised shares of Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. Leerink Partners reaffirmed an “outperform” rating and issued a $46.00 target price on shares of Vericel in a report on Tuesday, March 10th. Wall Street Zen downgraded shares of Vericel from a “buy” rating to a “hold” rating in a research note on Sunday, June 14th. HC Wainwright reiterated a “buy” rating and set a $64.00 price target on shares of Vericel in a report on Friday, May 8th. Finally, Truist Financial lowered their price target on Vericel from $48.00 to $42.00 and set a “buy” rating on the stock in a research report on Wednesday, April 15th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $52.50.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.